Indivior Pharmaceuticals, Inc. Revenue 2022–2025
Indivior Pharmaceuticals, Inc. reported $1.24B of revenue for fiscal 2025. That was 4.3% higher than fiscal 2024. Compared with fiscal 2022, the change was +37.5%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $1.24B | +4.3% |
| FY 2024 | $1.19B | +8.7% |
| FY 2023 | $1.09B | +21.3% |
| FY 2022 | $901.00M | — |
Source: Indivior Pharmaceuticals, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open INDV 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Indivior Pharmaceuticals, Inc. reported $1.24B of revenue for fiscal 2025. That was 4.3% higher than fiscal 2024. Compared with fiscal 2022, the change was +37.5%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Indivior Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeIndivior Pharmaceuticals, Inc. — frequently asked questions
What is Indivior Pharmaceuticals, Inc.'s revenue?
Indivior Pharmaceuticals, Inc. (INDV) reported revenue of $1.24B for fiscal year 2025, per its SEC filings.
How has Indivior Pharmaceuticals, Inc.'s revenue changed over time?
Between fiscal 2022 and 2025, INDV's revenue grew at roughly 11.2% per year (compound annual rate), from $901.00M to $1.24B.
Where does this data come from?
Figures are computed from Indivior Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.